Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$77.36
-1.2%
$70.03
$62.50
▼
$93.42
$15.23B0.973.06 million shs1.35 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%+5.40%+17.94%-1.99%+17.94%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$77.36
-1.2%
$70.03
$62.50
▼
$93.42
$15.23B0.973.06 million shs1.35 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%+5.40%+17.94%-1.99%+17.94%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.82
Moderate Buy$104.4234.98% Upside

Current Analyst Ratings Breakdown

Latest BBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetOverweight$88.00 ➝ $91.00
11/2/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetBuy$106.00 ➝ $108.00
10/30/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Reiterated RatingBuy
10/30/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Lower Price TargetBuy$110.00 ➝ $100.00
10/30/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetOverweight$87.00 ➝ $88.00
10/21/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Lower Price TargetOverweight$97.00 ➝ $87.00
10/19/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetOverweight$115.00 ➝ $120.00
10/19/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Lower Price TargetNeutral$94.00 ➝ $91.00
10/15/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Initiated CoverageBuy$82.00 ➝ $92.00
10/14/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UpgradeStrong-Buy
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M30.01N/AN/A($13.32) per share-5.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.04N/AN/AN/A-59.84%N/A-39.81%N/A

Latest BBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5423-$0.42+$0.1223-$0.42$293.47 million$353.17 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
2.09
2.03

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
839194.80 million167.08 millionOptionable

Recent News About These Companies

BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $91.00
BridgeBio Pharma stock nears key BBP-418 FDA decision
Barclays Keeps Their Buy Rating on BridgeBio Pharma (BBIO)
BridgeBio Pharma (BBIO) AI Stock Analysis

New MarketBeat Followers Over Time

Media Sentiment Over Time

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$77.36 -0.94 (-1.20%)
Closing price 04:00 PM Eastern
Extended Trading
$77.36 0.00 (-0.01%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.